Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease
Jeffrey R Liddell, Daniel Obando, Joe Liu, George Ganio, Irene Volitakis, Su San Mok, Peter J Crouch, Anthony R White, Rachel Codd
Free Radical Biology and Medicine | ELSEVIER SCIENCE INC | Published : 2013
Funding from the National Health and Medical Research Council (R.C., A.R.W.), the University of Sydney (R.C., J.L.), and Parkinson's NSW (R.C., A.R.W.) is gratefully acknowledged. The authors kindly thank Dr. Janetta Culvenor, University of Melbourne, for provision of the alpha-synuclein antibody.